Home > Insider Trading > Filing (0000805928-21-000163)

Filing Details

Accession Number:: 0000805928-21-000163
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-08-10 16:52:09
Reporting Period:: 2021-08-06

Accepted Time:: 2021-08-10 16:52:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
805928	Axogen Inc.	AXGN	Electromedical & Electrotherapeutic Apparatus (3845)	411301878

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1530968	L. Karen Zaderej	13631 Progress Boulevard Suite 400 Alachua FL 32615	Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-08-10	75,000	$5.09	855,018	No	4	M	Direct
Common Stock	Disposition	2021-08-06	14,756	$18.40	840,262	No	4	S	Direct
Common Stock	Disposition	2021-08-06	1,259	$19.18	839,003	No	4	S	Direct
Common Stock	Disposition	2021-08-06	22,902	$18.41	816,101	No	4	S	Direct
Common Stock	Disposition	2021-08-06	2,083	$19.16	814,018	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to purchase)	Disposition	2021-08-10	75,000	$5.09	75,000	$5.09

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
35,000		2022-12-29	No	4	M	Direct

Footnotes

The Reporting Person has elected to exercise and hold the shares at this time.
The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with a performance stock award that vested on February 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to 18.69, inclusive. The reporting person undertakes to provide to Axogen, Inc., any security holder of Axogen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with a performance stock award that vested on February 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.08 to 19.40, inclusive.
The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with the November 19, 2018 and December 19, 2018 stock option exercises. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.20 to 18.69, inclusive.
The reported shares were sold pursuant to an Approved Rule 10b5-1 Plan dated June 7, 2021, as defined under the Company's Insider Trading Policy, with proceeds in connection with the November 19, 2018 and December 19, 2018 stock option exercises. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.075 to 19.40, inclusive.
All shares of Common Stock underlying the employee stock option became fully vested on December 29, 2019 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2016 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.